IgG4-СВЯЗАННОЕ СИСТЕМНОЕ ЗАБОЛЕВАНИЕ. СОВРЕМЕННЫЙ ВЗГЛЯД НА «СТАРЫЕ» БОЛЕЗНИ

1. <div><p>Zhang L., Smyrk T.C. Autoimmune pancreatitis and IgG4-related systemic diseases. Int J Clin Exp Pathol 2010; 3: 491-504.</p><p>Aucouturier A., Danon F., Daveau M. et al. Measurement of serum IgG4 levels by a competitive immunoenzymatic assay with monoclonal antibodies. J Immun Meth 1984; 74: 151-62.</p><p>Meulenbroek A.J., Zeijlemaker W.P. Human IgG Subclasses: useful diagnostic markers for immunocompetence [online]. Sanquin, Laboratory for Experimental and Clinical Immunology University of Amsterdam, the Netherlands; 1996 (http://www.xs4all.nl/_ednieuw/IgGsubclasses/subkl.htm).</p><p>Salfeld J.G. Isotype selection in antibody engineering. Nat Biotechnol 2007; 25: 1369-72.</p><p>Aalberse R.C., Stapel S.O., Schuurman J. et al. Immunoglobulin G4: an odd antibody. Clin Exp Allergy 2009; 39: 469-77.</p><p>Zen Y., Fujii T., Harada K. et al. Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis. Hepatology 2007; 45(6): 1538-46.</p><p>Aalberse R.C., Platts-Mills T.A. How do we avoid developing allergy: modifications of the TH2 response from a B-cell perspective. J Allergy Clin Immunol 2004; 113: 983-6.</p><p>Kawa S., Ota M., Yoshizawa K. et al. HLA DRB10405-DQB10401 haplotype is associated with autoimmune pancreatitis in the Japanese population. Gastroenterology 2002; 122: 1264-9.</p><p>Scalapino K.J., Daikh D.I. CTLA-4: a key regulatory point in the control of autoimmune disease. Immunol Rev 2008; 223: 143-55.</p><p>Chang M.C., Chang Y.T., Tien Y.W. et al. T-cell regulatory gene CTLA-4 polymorphism/haplotype association with autoimmune pancreatitis. Clin Chem 2007; 53: 1700-5.</p><p>Umemura T., Ota M., Hamano H. et al. Association of autoimmune pancreatitis with cytotoxic T-lymphocyte antigen 4 gene polymorphisms in Japanese patients. Am J Gastroenterol 2008; 103: 588-94.</p><p>Okazaki K., Uchida K., Ohana M. et al. Autoimmune-related pancreatitis is associated with autoantibodies and a Th1/Th2-type cellular immune response. Gastroenterology 2000; 118: 573-81.</p><p>Aparisi L., Farre A., Gomez-Cambronero L. et al. Antibodies to carbonic anhydrase and IgG4 levels in idiopathic chronic pancreatitis: relevance for diagnosis of autoimmune pancreatitis. Gut 2005; 54: 703-9.</p><p>Nishimori I., Miyaji E., Morimoto K. et al. Serum antibodies to carbonic anhydrase IV in patients with autoimmune pancreatitis. Gut 2005; 54: 274-81.</p><p>Asada M., Nishio A., Uchida K. et al. Identification of a novel autoantibody against pancreatic secretory trypsin inhibitor in patients with autoimmune pancreatitis. Pancreas 2006; 33: 20-6.</p><p>Löhr J.M., Faissner R., Koczan D. et al. Autoantibodies against the exocrine pancreas in autoimmune pancreatitis: gene and protein expression profiling and immunoassays identify pancreatic enzymes as a major target of the inflammatory process. Am J Gastroenterol 2010; 105: 2060-71.</p><p>Yamamoto M., Naishiro Y., Suzuki C. et al. Proteomics analysis in 28 patients with systemic IgG4-related plasmacytic syndrome. Rheumatol Int 2010; 30: 565-8.</p><p>Akitake R., Watanabe T., Zaima C. et al. Possible involvement of T helper type 2 responses to Toll-like receptor ligands in IgG4-related sclerosing disease. Gut 2010; 59: 542-5.</p><p>Miyake K., Moriyama M., Aizawa K. et al. Peripheral CD4 T cells showing aTh2 phenotype in a patient with Mikulicz's disease associated with lymphadenopathy and pleural effusion. Mod Rheumatol 2008; 18: 86-90.</p><p>Kudo-Tanaka E., Nakatsuka S., Hirano T. et al. A case of Mikulicz's disease with Th2-biased cytokine profile: possible feature discriminable from Sjö gren's syndrome. Mod Rheumatol 2009; 19: 691-5.</p><p>Suzuki K., Tamaru J.I., Okuyama A. et al. IgG4-positive multiorgan lymphoproliferative syndrome manifesting as chronic symmetrical sclerosing dacryo-sialadenitis with subsequent secondary portal hypertension and remarkable IgG4-linked il 4 elevation. Rheumatology (Oxford) 2010; 49: 1789-91.</p><p>Kanari H., Kagami S., Kashiwakuma D. et al. Role of Th2 cells in IgG4-related lacrimal gland enlargement. Int Arch Allergy Immunol 2010; 152(Suppl. 1): 47-53.</p><p>Zen Y., Fujii T., Harada K et al. Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis. Hepatology 2007; 45(6): 1538—46.</p><p>Koyabu M., Uchida K., Miyoshi H. et al. Analysis of regulatory T cells and IgG4-positive plasma cells among patients of IgG4-related sclerosing cholangitis and autoimmune liver diseases. J Gastroenterol 2010; 45: 732-41.</p><p>Miyoshi H., Uchida K., Taniguchi T. et al. Circulating naive and CD4+CD25high regulatory T cells in patients with autoimmune pancreatitis. Pancreas 2008; 36: 133-40.</p><p>Detlefsen S., Sipos B., Zhao J. et al. Autoimmune pancreatitis: expression and cellular source of profibrotic cytokines and their receptors. Am J Surg Pathol 2008; 32: 986-95.</p><p>Kamisawa T., Anjiki H., Egawa N., Kubota N. Allergic manifestations in autoimmune pancreatitis. Eur J Gastroenterol Hepatol 2009; 21: 1136-9.</p><p>Sah R.P., Pannala R., Zhang L. et al. Eosinophilia and allergic disorders in autoimmune pancreatitis. Am J Gastroenterol 2010. doi: 10.1038/ ajg.2010.236 [Epub. ahead of print].</p><p>Kojima M., Sipos B., Klapper W. et al. Autoimmune pancreatitis: frequency, IgG4 expression, and clonality of T and B cells. Am J Surg Pathol 2007; 31: 521-8.</p><p>Song M.H., Kim M.H., Jang S.J. et al. Comparison of histology and extracellular matrix between autoimmune and alcoholic chronic pancreatitis. Pancreas 2005; 30: 272-8.</p><p>Suda K., Nishimori I., Takase M. et al. Autoimmune pancreatitis can be classified into early and advanced stages. Pancreas 2006; 33: 345-50.</p><p>Dhall D., Suriawinata A.A., Tang L.H. et al. Use of immunohistochemistry for IgG4 in the distinction of autoimmune pancreatitis from peritumoral pancreatitis. Human Pathol 2010; 41: 643-52.</p><p>Geyer J.T., Deshpande V. IgG4-associated sialadenitis. Curr Opin Rheumatol 2011; 23: 95-101.</p><p>Smyrk T.C. Pathological features of IgG4-related sclerosing disease. Curr Opin Rheumatol 2011; 23(1): 74-9</p><p>Masaki Y., Dong L., Kurose N. et al. Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis 2009; 68: 1310-5.</p><p>Yoshida K., Toki F., Takeuchi T. et al. Chronic pancreatitis caused by an autoimmune abnormality: proposal of the concept of autoimmune pancreatitis. Dig Dis Sci 1995; 40: 1561-8.</p><p>Montano-Loza A.J., Lalor E., Mason A.L. Recognizing immunoglobulin G4-related overlap syndromes in patients with pancreatic and hepatobiliary diseases. Can J Gastroenterol 2008; 22(10): 840-6.</p><p>Chari S.T., Kloeppel G., Zhang L. et al. Histopathologic and clinical subtypes ofautoimmune pancreatitis: the Honolulu consensus document. Pancreas 2010; 39: 549-54.</p><p>Okazaki K., Kawa S., Kamisawa T. et al. Japanese clinical guidelines for autoimmune pancreatitis. Pancreas 2009; 38: 849-66.</p><p>Kamisawa T., Egawa N., Nakajima H. et al. Extrapancreatic lesions in autoimmune pancreatitis. J Clin Gastroenterol 2005; 39: 904-7.</p><p>Kamisawa T., Funata N., Hayashi Y. et al. A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol 2003; 38: 982-4.</p><p>Kamisawa T., Nakajima H., Egawa N. et al. IgG4-related sclerosing disease incorporating sclerosing pancreatitis, cholangitis, sialadenitis and retroperitoneal fibrosis with lymphadenopathy. Pancreatology 2006; 6: 132-7.</p><p>Kamisawa T., Okamoto A. Autoimmune pancreatitis: proposal of IgG4-related sclerosing disease. J Gastroenterol 2006; 41: 613—25.</p><p>Okazaki K., Kawa S., Kamisawa T. et al. Clinical diagnostic criteria of autoimmune pancreatitis: revised proposal. J Gastroenterol 2006; 41: 626—31</p><p>Zamboni G., Luttges J., Capelli P. et al. Histopathological features of diagnostic and clinical relevance in autoimmune pancreatitis: a study on 53 resection specimens and 9 biopsy specimens. Virch Arch 2004; 445: 552-63.</p><p>Park D.H., Kim M.H., Chari S.T. Recent advances in autoimmune pancreatitis. Gut 2009; 58: 1680-9.</p><p>Kamisawa T., Okamoto A. IgG4-related sclerosing disease. World J Gastroenterol 2008; 14: 3948-55.</p><p>Chari S.T., Takahashi N., Levy M.J. et al. A diagnostic strategy to distinguish autoimmune pancreatitis from pancreatic cancer. Clin Gastroenterol Hepatol 2009; 10: 1097-103.</p><p>Okazaki K., Kawa S., Kamisawa T. et al. Japanese consensus guidelines for management of autoimmune pancreatitis. I: Concept and diagnosis of autoimmune pancreatitis. J Gastroenterol 2010; 45: 249-65.</p><p>Kamisawa T., Takuma K., Egawa N. et al. Autoimmune pancreatitis and IgG4-related sclerosing disease. Nat Rev Gastroenterol Hepatol 2010; 4: 401—9.</p><p>Raina A., Krasinskas A.M., Greer J.B. et al. Serum immunoglobulin G fraction 4 levels in pancreatic cancer: elevations not associated with autoimmune pancreatitis. Arch Pathol Lab Med 2008; 132: 48-53.</p><p>Ghazale A., Chari S.T., Smyrk T.C. et al. Value of serum IgG4 in the diagnosis of autoimmune pancreatitis and in distinguishing it from pancreatic cancer. Am J Gastroenterol 2007; 102: 1646—53.</p><p>Kamisawa T., Shimosegawa T., Okazaki K. et al. Standard steroid treatment for autoimmune pancreatitis. Gut 2009; 58: 1504—7.</p><p>LaRusso N.F., Wiesner R.H., Ludwig J. et al. Current concepts. Primary sclerosing cholangitis. N Engl J Med 1984; 310: 899—903.</p><p>Wiesner R.H., Grambsch P.M., Dickson E.R. et al. Primary sclerosing cholangitis: natural history, prognostic factor and survival analysis. Hepatology 1989; 10: 430-6.</p><p>Kamisawa T., Takuma K., Anjiki H. et al. Sclerosing cholangitis associated with autoimmune pancreatitis differs from primary sclerosing cholangitis. World J Gastroenterol 2009; 15: 2357—60.</p><p>Hamano H., Kawa S., Uehara T. et al. Immunoglobulin G4-related lymphoplasmacytic sclerosing cholangitis that mimics infiltrating hilar cholangiocarcinoma: part of a spectrum of autoimmune pancreatitis? Gastrointest Endosc 2005; 62: 152—7.</p><p>Hayashi K., Nakazawa T., Ohara H. et al. Autoimmune sclerosing cholangiopancreatitis with little pancreatic involvements by imaging findings. Hepatogastroenterology 2007; 54: 2146-51.</p><p>Nishino T., Oyama H., Hashimoto E. et al. Clinicopathological differences between sclerosing cholangitis with autoimmune pancreatitis and primary sclerosing cholangitis. J Gastroenterol 2007; 42: 550—9.</p><p>Alderlieste Y.A., Elzen B.D.J., Rauws E.A.J. et al. Immunoglobulin G4-associated cholangitis: one variant of immunoglobulin G4-related systemic disease. Digestion 2009; 79: 220—8.</p><p>Bjornsson E., Chari S., Sliveira M. et al. Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy. Am J Ther (in press).</p><p>Mikulicz J. Uber eine eigenartige symmetrische erkrankung der thrä nen- und mundspeicheldrü sen. In: Billroth T., ed. Beiträ ge zur chirurgie festschrift gewidmet. Stuttgart: Ferdinand Enke, 1892; 610—30.</p><p>Cимонова М.В., Васильев В.И., Корнилова Н.Н. и др. Дифференциальная диагностика болезни Микулича и болезни Шегрена. Стоматология 1988; 3: 71-3.</p><p>Mikulicz J. Concerning a peculiar symmetrical disease of the lacrimal and salivary glands. Modern Classics 1937—1938; 2: 165—86.</p><p>Morgan W. S., Castleman B. A clinicopathologic study of Mikulicz's disease.Am J Pathol 1953; 29: 471-503.</p><p>Васильев В.И., Пальшина С.Г., Симонова М.В. и др. Первый опыт использования ритуксимаба в терапии болезни Микулича. Тер. арх. 2010; 6: 62-6.</p><p>Sjögren H. Zur Kenntnis der Keratoconjunctivitis Sicca (Keratitis filiformis bei Hypofunktion der Tranendrusen). Acta Ophthalmol 1933(Suppl. II): 1—151.</p><p>Morgan W.S. The probable systemic nature of Mikulicz's disease and its relation to Sjogren's syndrome. N Engl J Med 1954; 251: 5—10.</p><p>MacLean H., Ironside J.W., Cullen J.F., Butt Z. Mikulicz syndrome and disease: 2 case reports high-lighting the difference. Acta Ophthalmol (Copenh) 1993; 71: 136-41.</p><p>Yamamoto M., Harada S., Ohara M. et al. Clinical and pathological differences between Mikulicz's disease and Sjogren's syndrome. Rheumatology (Oxford) 2005; 44: 227-34.</p><p>Yamamoto M., Takahashi H., Ohara M. et al. A new conceptualization for Mikulicz's disease as an IgG4-related plasmacytic disease. Mod Rheumatol 2006; 16: 335-40</p><p>Kubota K., Wada T., Kato S. et al. Highly active state of autoimmune pancreatitis with Mikulicz's disease. Pancreas 2010; 39: e6—e10.</p><p>Kü ttner H. Uber entzundiche tumoren der submaaxillar-speicheldruse. Beitr Klin Chir 1896; 15: 815-34.</p><p>Chan J.K. Kuttner tumor (chronic sclerosing sialadenitis) of the submandibular gland: an underrecognized entity. Adv Anat Pathol 1998; 5: 239—51.</p><p>Chow T.L., Chan T.T., Choi C.Y., Lam S.H. Kuttner's tumour (chronic sclerosing sialadenitis) of the submandibular gland: a clinical perspective. Hong Kong Med J 2008; 14: 46-9.</p><p>Harrison J.D., Epivatianos A., Bhatia S.N. Role of microliths in the aetiology of chronic submandibular sialadenitis: a clinicopathological investigation of 154 cases. Histopathology 1997; 31: 237—51.</p><p>Rasanen O., Jokinen K., Dammert K. Sclerosing inflammation of the submandibular salivary gland (Kuttner tumour): a progressive plasmacellular ductitis. Acta Otolaryngol 1972; 74: 297—301.</p><p>Isacsson G., Isberg A., Haverling M., Lundquist P.G. Salivary calculi and chronic sialoadenitis of the submandibular gland: a radiographic and histologic study. Oral Surg Oral Med Oral Pathol 1984; 58: 622-7.</p><p>Tiemann M., Teymoortash A., Schrader C. et al. Chronic sclerosing sialadenitis of the submandibular gland is mainly due to a T lymphocyte immune reaction. Mod Pathol 2002; 15: 845—52.</p><p>Kamisawa T., Nakajima H., Hishima T. Close correlation between chronic sclerosing sialadenitis and immunoglobulin G4. Intern Med J 2006; 36: 527-9.</p><p>Takano K.I., Yamamoto M., Takahashi H. et al. Clinicopathologic similarities between Mikulicz disease and Kü ttner tumor. Am J Otolaryngol 2009 Oct 30 [Epub. ahead of print].</p><p>Jacobs D., Galetta S. Diagnosis and management of orbital pseudotumour. Curr Opin Ophthalmol 2002; 13: 347-51.</p><p>Mombaerts I., Goldschmeding R., Schlingemann R.O., Koornneef L. What is orbital pseudotumour? Surv Ophthalmol 1996; 41: 66—78.</p><p>Rootman J., Nugent R. The classification and management of acute orbital pseudotumours. Ophthalmology 1982; 89: 1040-8.</p><p>Shikishima K., Kawai K., Kitahara K. Pathological evaluation of orbital tumours in Japan: analysis of a large case series and 1379 cases reported in the Japanese literature. Clin Exp Ophthalmol 2006; 34: 239-44.</p><p>Yuen S.J.A., Rubin P.A.D. Idiopathic orbital inflammation: ocular mechanisms and clinicopathology. Ophthalmol Clin North Am 2002; 15: 121-6.</p><p>Leone C.R. Jr, Lloyd W.C. 3rd. Treatment protocol for orbital inflammatory disease. Ophthalmology 1985; 92: 1325-31.</p><p>Orcutt J.C., Garner A., Henk J.M. et al. Treatment of idiopathic inflammatory orbital pseudotumours by radiotherapy. Br J Ophthalmol 1983; 67: 570-4.</p><p>Rootman J., McCarthy M., White V. et al. Idiopathic sclerosing inflammation of the orbit. A distinct clinicopathologic entity. Ophthalmology 1994; 101: 570-84.</p><p>Abramovitz J.N., Kasdon D.L., Sutula F. et al. Sclerosing orbital pseudotumour. Neurosurgery 1983; 12: 463-8.</p><p>Weissler M.C, Miller E., Fortune M.A. Sclerosing orbital pseudotumour: a unique clinicopathologic entity. Ann Otol Rhinol Laryngol 1989; 98: 496-501.</p><p>McCarthy J.M., White V.A., Harris G. et al. Idiopathic sclerosing inflammation of the orbit: immunohistologic analysis and comparison with retroperitoneal fibrosis. Mod Pathol 1993; 6: 581-7.</p><p>Swamy B.N., McCluskey P., Nemet A. Idiopathic orbital inflammatory syndrome: Clinical features and treatment outcomes. Br J Ophthalmol 2007; 91(12): 1667-70.</p><p>Kamisawa T., Yoshiike M., Egawa N. et al. Treating patients with autoimmune pancreatitis: results from a long-term follow-up study. Pancreatology 2005; 5: 234-8.</p><p>Chari S.T., Smyrk T.C., Levy M.J. et al. Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience. Clin Gastroenterol Hepatol 2006; 4: 1010-6.</p><p>Wakabayashi T., Kawaura Y., Satomura Y. et al. Long-term prognosis of duct-narrowing chronic pancreatitis: strategy for steroid treatment. Pancreas 2005; 30: 31-9.</p><p>Kubota K., Iida H., Fujisawa T. et al. Clinical factors predictive of spontaneous remission or relapse in cases of autoimmune pancreatitis. Gastrointest Endosc 2007; 66: 1142-51.</p><p>Park D.H., Kim M.H., Chari S.T. Recent advances in autoimmune pancreatitis. Gut 2009; 58: 1680-9.</p><p>Kamisawa T., Chung J.B., Irie H. et al. Japan-Korea Symposium on Autoimmune Pancreatitis (KOKURA 2007). Pancreas 2007; 35: 281-4.</p><p>Ito T., Nishimori I., Inoue N. et al. Treatment for autoimmune pancreatitis: consensus on the treatment for patients with autoimmune pancreatitis in Japan. J Gastroenterol 2007; 42(Suppl. 18): 50-8.</p><p>Ko S.B., Mizuno N., Yatabe Y. et al. Corticosteroids correct aberrant CFTR localization in the duct and regenerate acinar cells in autoimmune pancreatitis. Gastroenterology 2010; 138: 1988-96.</p><p>Kamisawa T., Shimosegawa T., Okazaki K. et al. Standard steroid treatment for autoimmune pancreatitis. Gut 2009; 58: 1504-7.</p><p>Kamisawa T., Okazaki K., Kawa S. et al. Japanese consensus guidelines for management of autoimmune pancreatitis: III. Treatment and prognosis of AIP. J Gastroenterol 2010; 45: 471-7.</p><p>Kim H.M., Chung M.J., Chung J.B. Remission and relapse of autoimmune pancreatitis: focusing on corticosteroid treatment. Pancreas 2010; 39: 555-60.</p><p>Pannala R., Chari S.T. Corticosteroid treatment for autoimmune pancreatitis. Gut 2009; 58: 1438-9.</p><p>Hirano K., Tada M., Isayama H. et al. Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. Gut 2007; 56: 1719-24.</p><p>Church N.I., Pereira S.P., Deheragoda M.G. et al. Autoimmune pancreatitis: clinical and radiological features and objective response to steroid therapy in a UK series. Am J Gastroenterol 2007; 102: 2417-25.</p><p>Khosroshahi A., Bloch D.B., Deshpande V., Stone J.H. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthr Rheum 2010; 62: 1755-62.</p><p>Pennisi A., Li X., Ling W. et al. The proteasome inhibitor, borte-zomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol 2009; 84: 6-14.</p><p>Khan M.L., Colby T.V., Viggiano R.W., Fonseca R. Treatment with bortezomib of a patient having hyper IgG4 disease. Clin Lymphoma Myeloma Leuk 2010; 10: 217-9.</p></div><br />